Simvastatin Normalizes Autonomic Neural Control in Experimental Heart Failure
- 20 May 2003
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 107 (19), 2493-2498
- https://doi.org/10.1161/01.cir.0000065606.63163.b9
Abstract
Background— HMG-CoA reductase inhibitors (statins) have been shown to beneficially affect outcomes in chronic heart failure (CHF). We hypothesized that statins exert effects on autonomic function, as assessed by plasma norepinephrine levels, direct recordings of renal sympathetic nerve activity (RSNA), and baroreflex function. Methods and Results— Normolipidemic CHF rabbits were treated with simvastatin or vehicle. CHF was induced by continuous ventricular pacing at 320 to 340 bpm for 3 weeks. Two to 3 days after instrumentation of the rabbits with renal nerve electrodes and arterial and venous catheters, blood samples and RSNA recordings were obtained in the conscious state. Baroreflex function was assessed after administration of sodium nitroprusside and phenylephrine. Mean baseline RSNA (±SEM) in normal rabbits was 19.3±3.8%; in CHF rabbits, 39.4±2.9% ( P −1 · d −1 ) simvastatin, 39.8±8.3% ( P −1 · d −1 ), 21.1±4.5% ( P =NS). Similar data were observed for plasma norepinephrine. In CHF rabbits treated with 3 mg · kg −1 · d −1 simvastatin, baroreflex regulation of heart rate to transient hypotension with sodium nitroprusside was normalized by 66% compared with CHF controls. Conclusions— These are the first data showing that non–lipid-lowering statin effects include a normalization of sympathetic outflow and reflex regulation in CHF. The precise neural and cellular pathways involved in these responses need further clarification. This finding may have important implications for the treatment of CHF and progression of the disease process.Keywords
This publication has 26 references indexed in Scilit:
- Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) TrialCirculation, 2002
- Effects of Sustained-Release Moxonidine, an Imidazoline Agonist, on Plasma Norepinephrine in Patients With Chronic Heart FailureCirculation, 2002
- The Regulation of Sympathetic Outflow in Heart FailureAnnals of the New York Academy of Sciences, 2001
- HMG-CoA Reductase Inhibitors: Is the Endothelium the Main Target?JMIR AI, 2001
- Heart rate variability patterns before ventricular tachycardia onset in patients with an implantable cardioverter defibrillatorThe American Journal of Cardiology, 2000
- Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effectsKidney International, 2000
- Follow-up study of patients randomized in the scandinavian simvastatin survival study (4S) of cholesterol loweringThe American Journal of Cardiology, 2000
- Neuroprotection mediated by changes in the endothelial actin cytoskeletonJCI Insight, 2000
- Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.JCI Insight, 1998
- Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamineLife Sciences, 1977